Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study

Eshan Vasudeva,1 Nathalie Moise,2 Chen Huang,3,4 Antoinette Mason,5 Joanne Penko,5 Lee Goldman,1 Pamela G. Coxson,5 Kirsten Bibbins-Domingo,5 and Andrew E. Moran1,2

BACKGROUND
We compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according to 2014 US hypertension treatment guidelines.

METHODS
The cardiovascular disease (CVD) policy model simulated CVD events, quality-adjusted life years (QALYs), and treatment costs in 35- to 74-year-old adults with untreated hypertension. CVD incidence, mortality, and risk factor levels were obtained from cohort studies, hospital registries, vital statistics, and national surveys. Stage 1 hypertension was defined as blood pressure 140–149/90–99 mm Hg; stage 2 hypertension as ≥150/100 mm Hg. Probabilistic input distribution sampling informed 95% uncertainty intervals (UIs). Incremental cost-effectiveness ratios (ICERs) < $50,000/QALY gained were considered cost-effective.

RESULTS
Treating 0.7 million hypertensive non-Hispanic black adults would prevent about 8,000 CVD events annually; treating 3.4 million non-Hispanic whites would prevent about 35,000 events. Overall 2014 guideline implementation would be cost saving in both groups compared with no treatment. For stage 1 hypertension but without diabetes or chronic kidney disease, cost savings extended to non-Hispanic black males ages 35–44 but not same-aged non-Hispanic white males (ICER $57,000/QALY; 95% UI $15,000–$100,000) and cost-effectiveness extended to non-Hispanic black females ages 35–44 (ICER $46,000/QALY; $17,000–$76,000) but not same-aged non-Hispanic white females (ICER $181,000/QALY; $111,000–$235,000).

CONCLUSIONS
Compared with non-Hispanic whites, cost-effectiveness of implementing hypertension guidelines would extend to a larger proportion of non-Hispanic black hypertensive patients.

Keywords: blood pressure; cost-effectiveness; hypertension; race.

doi:10.1093/ajh/hpw047

Our recent cost-effectiveness modeling study found that implementing 2014 US hypertension guidelines would be cost saving overall in untreated hypertensive adults aged 35–74 years old, but cost-effectiveness did not extend to primary of 35- to 44-year-old women with stage 1 hypertension for primary cardiovascular disease (CVD) prevention. Given their higher CVD risk, we hypothesized that hypertension treatment would be more cost-effective in young and middle-aged non-Hispanic blacks compared with same-aged non-Hispanic whites. We therefore compared the cost-effectiveness of implementing 2014 hypertension guidelines in untreated non-Hispanic black and non-Hispanic white patients overall and by age, sex, hypertension stage, and CVD, diabetes, and chronic kidney disease (CKD) status.
METHODS

CVD policy model

The CVD policy model is a computer-simulation, state-transition model of incidence, prevalence, mortality, and costs of CVD in the United States (Supplementary Figure). The primary study population included non-Hispanic black and white men and women aged 35–74 in 2014 who were not receiving pharmacotherapy for hypertension. We restricted our analysis to currently untreated hypertensive patients because we were not able to discern among different causes of uncontrolled BP in already treated patients (financial obstacles, nonadherence, side effects, or contraindications due to comorbidities). Adults aged 75 years and older were excluded from this analysis due to highly variable rates of medication-related adverse events.6 We were unable to analyze Hispanic Americans or Asian Americans at this time due to insufficient contemporary CVD incidence data for these heterogeneous groups.

Means or proportions and joint distributions of risk factors, including systolic and diastolic BP, cholesterol, and hypertension medication use, smoking, diabetes, and CKD status, were estimated from pooled National Health and Nutrition Examination Surveys (NHANES) 2007–2010 by 10-year age categories, sex, and race/ethnic group. NHANES 2007–2010 systolic BP was categorized into 3 main categories: <140, 140–159 (stage 1 hypertension), and ≥160 mm Hg (stage 2 hypertension). To assess 2014 guideline treatment recommendations in older adults (ages 60–74 years), stage 1 systolic BP was further divided into the intervals 140–149 and 150–159 mm Hg. Diastolic BP categories were <90, 90–99 (stage 1), and ≥100 mm Hg (stage 2). Hypertensive patients were considered untreated if they answered no to both NHANES questions: “Because of your high blood pressure/hypertension, have you ever been told to take prescribed medicine?” and “Are you currently taking medication to lower your blood pressure?”

Default multivariate stroke and coronary heart disease incidence functions were estimated in an original Framingham Heart Study analysis. The CVD policy model simulated CVD events, non-CVD deaths, quality-adjusted life years (QALYs), and hypertension and CVD treatment costs of implementing 2014 US treatment guidelines in untreated hypertensive non-Hispanic black and white adults aged 35–74 years compared with no treatment.

Race/ethnic-specific CVD policy models

While the structure of both the non–Hispanic black and non–Hispanic white CVD policy model versions is identical to that of the national model, several inputs were re-populated with data specific to non–Hispanic blacks and non–Hispanic whites (for details, see Supplementary Text).

Population projections for the years 2014–2024 were obtained from 2010 US Census Bureau. National Health Interview Survey data were used to estimate the proportion of adults with known coronary heart disease, stroke, or both these conditions. All beta coefficients for the effect of non–BP risk factors on incident stroke (diabetes, CKD, and smoking) and on incident coronary heart disease (cholesterols, diabetes, CKD, and smoking) were estimated from Framingham Heart Study data. Numbers of 2010 CVD deaths (stroke [ICD-10 codes I60–I69], coronary heart disease [I20–I25 and two-thirds of I14, I15, and I16], and hypertensive heart disease deaths [I11.0, I11.9]) and non-CVD deaths (remainder of ICD codes) reported by the Centers for Disease Control (CDC WONDER) for 2010 were used as model calibration targets.

Hypertension treatment model inputs

The 2014 US hypertension guidelines ("JNC 8") recommended a goal of <140/90 mm Hg for diabetes and/or CKD, diastolic BP < 90 if age under 60 years and BP < 150/90 if
age > 60 years without diabetes or CKD. The number of US non-Hispanic black and white adults eligible for treatment under JNC 8 was estimated using these categories and BP and treatment status information in NHANES 2007–2010.

BP change due to antihypertensive medications was determined by pretreatment BP and the number of standard doses of medications needed to reach the guideline BP goal, according to a trials-based formula. BP changes were calculated based on pretreatment BP, age, and sex. We assumed the same BP reduction per standard dose of the main drug classes (Table 1; Supplementary Text). Quality of life penalties were applied for side effects. Treatment costs included hypertension monitoring costs, drug side effects, and the average wholesale cost of drugs. We assumed the 75% adherence observed in the same clinical trials meta-analysis that provided the association between BP reduction and CVD risk reduction. In our prior analysis, lower adherence reduced effectiveness and costs proportionally; thus, lower adherence reduced population impact but had little effect on cost-effectiveness.

We assumed CVD risk reduction is due to BP reduction, and that BP is lowered to a similar extent across classes when comparing per-class standard doses. We started with observational Prospective Studies Collaboration age-specific relative risks and 95% confidence intervals for coronary heart disease and stroke per 10 mm Hg change in systolic BP or 5 mm Hg diastolic BP (Table 1). Age-specific relative risk inputs were calibrated to be within ±0.02 of these estimates and overall relative risks within 95% confidence interval bounds of the summary estimate from a large meta-analysis of randomized clinical trials of hypertension treatment (Supplementary Tables 2 and 3). The stroke relative risk estimate was found to be close to the pooled estimate from the East Asian trials included in that analysis (0.59 (0.49–0.71); Supplementary Text). The resulting relative risk assumptions were validated for treatment of systolic BP in ages 60–74 years by simulating the treatment and placebo groups of the Systolic Hypertension in the Elderly Program (SHEP) trial and comparing simulated relative rate ratios with those observed in the trial (Supplementary Text; Supplementary Table 4).

Main analysis

A status quo simulation projected CVD events, CVD deaths, and heart failure deaths, costs, and QALYs for non-Hispanic black and white adults aged 35–74 years with untreated hypertension from 2014 to 2024. We then simulated CVD outcomes treating to JNC 8 BP targets in non-Hispanic blacks and whites with subgroup analysis stratified by age groups (under and over 60 years) and status of CVD, CKD, or diabetes. Incremental cost-effectiveness ratios (ICERs) were calculated as change in costs divided by incremental change in QALYs. ICERs < $50,000/QALY gained were considered cost-effective, ≥$50,000 and < $150,000 of intermediate value, and ≥$150,000 of low value. All analyses were approached from a payer’s perspective. Future costs and QALYs were discounted at 3% per year. ICERs compared costs and costs savings associated with treating patients to JNC 8 guidelines vs. no treatment within age groups and by CVD, diabetes, and CKD status.

In an exploratory analysis, we simulated alternative scenarios applying nonpharmacologic diet and exercise (lifestyle) interventions alone to lower BP in stage 1 hypertension without diabetes or CKD based on the upper and lower 95% confidence interval bounds of a summary effectiveness estimate from lifestyle intervention trials. Reduction in total cardiovascular events due to lifestyle interventions was estimated, but cost analysis for lifestyle intervention was not done due to poor and inconsistent data available on the cost of these interventions.

Multivariate, probabilistic sensitivity analysis

We did not perform 1-way sensitivity analyses since uncertainties surrounding each model input were explored extensively in our prior analysis. Uncertainty distributions of the main inputs, including clinical effectiveness of BP lowering, relative risk of CVD associated with BP change, quality of life decrements due to side effects, and costs related to side effects, medications, and monitoring, were randomly sampled 1,000 times in probabilistic simulations. From these results, we calculated 95% uncertainty intervals (UIs) for all model outputs.

RESULTS

About 130,000 non-Hispanic blacks and 570,000 non-Hispanic whites with CVD and hypertension but not currently treated with medications would be eligible for secondary prevention every year during the 2014–2024. Treating these patients was estimated to prevent about 2,000 and 10,000 CVD events in black and white populations, respectively (Table 2). Additionally, 1.7 million non-Hispanic blacks and 5.4 million non-Hispanic whites aged 35–74 years with hypertension were eligible for primary prevention treatment. Treating these patients to 2014 guideline targets was projected to prevent about 6,000 and 25,000 CVD events in non-Hispanic black and non-Hispanic white populations, respectively (Table 2).

Hypertension treatment was cost-saving overall in both non-Hispanic blacks and non-Hispanic whites compared with no treatment (Table 2). Incremental addition of treatment of stage 1 hypertension for primary prevention to treatment of CVD and stage 2 patients was also cost-effective in both groups overall. When treatment was assessed in progressively less cost-effective strategies, cost savings were observed in a greater proportion of subgroups in the non-Hispanic black population compared with the non-Hispanic white adults. In non-Hispanic blacks, treating hypertension for primary prevention in males of all ages and BP stages was cost-saving, regardless of diabetes or CKD status (Figure 1). Treatment was also cost-saving in all non-Hispanic black women with stage 2 hypertension and in those aged 45–74 years with stage 1 hypertension. Treating non-Hispanic black women aged 35–44 years with stage 1 hypertension was cost-effective both in those with diabetes or CKD ($21,000/QALY;
### Table 1. Main assumptions and uncertainty ranges used for the comparative effectiveness analysis of US BP treatment guidelines

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate (range in upper and lower bound estimates if a variation assumed according to age and/or sex)</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Main</strong></td>
<td><strong>Lower</strong></td>
</tr>
<tr>
<td><strong>Effectiveness</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average RR per 5 mm Hg reduction in diastolic BP or 10 mm Hg reduction in systolic BP, ages 35–59 years&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD</td>
<td>0.73 (0.72–0.74)</td>
<td>0.70 (0.67–0.72)</td>
</tr>
<tr>
<td>Stroke</td>
<td>0.64 (0.61–0.66)</td>
<td>0.59 (0.54–0.63)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>0.86 (0.83–0.89)</td>
<td>0.76</td>
</tr>
<tr>
<td>Average RR per 10 mm Hg reduction in systolic BP or 5 mm Hg reduction in diastolic BP, ages 60–74 years&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD</td>
<td>0.77 (0.74–0.78)</td>
<td>0.74 (0.72–0.76)</td>
</tr>
<tr>
<td>Stroke</td>
<td>0.69 (0.66–0.71)</td>
<td>0.64 (0.62–0.64)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>0.91 (0.91–0.92)</td>
<td>0.80</td>
</tr>
<tr>
<td><strong>Average systolic BP-lowering effect (mm Hg)&lt;sup&gt;b&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 2 hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;60 years, pretreatment ≥160 mm Hg target 140 mm Hg, 3–4 standard dose medications</td>
<td>31.0–34.7</td>
<td>26.0–29.4</td>
</tr>
<tr>
<td>Age ≥60 years, pretreatment ≥160 mm Hg target 150 mm Hg, 2–3 standard dose medications</td>
<td>22.1–24.2</td>
<td>18.1–18.9</td>
</tr>
<tr>
<td>Stage 1 hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;60 years, pretreatment 140–159 mm Hg target 140 mm Hg, 0.5–2.0 standard dose medications</td>
<td>7.9–10.9</td>
<td>5.9–8.3</td>
</tr>
<tr>
<td>Age ≥60 years, pretreatment 150–159 mm Hg target 150 mm Hg, 0.5 standard dose medications</td>
<td>7.1</td>
<td>3.2</td>
</tr>
<tr>
<td><strong>Diastolic BP-lowering effect (mm Hg)&lt;sup&gt;b&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ages, stage 2 hypertension (≥100 mm Hg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ages (target 90 mm Hg, 3 standard dose medications)</td>
<td>17.1</td>
<td>12.0</td>
</tr>
<tr>
<td>All ages, stage 1 hypertension (90–99 mm Hg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ages (target 90 mm Hg, 1 standard dose medication)</td>
<td>5.3</td>
<td>3.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Annual costs per person treated (2010 costs; inflated to 2014 costs in all results)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician office visit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment monitoring visits (number)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 2 hypertension</td>
<td>4</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Stage 1 hypertension</td>
<td>3</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Cost per routine monitoring visit</td>
<td>$71</td>
<td>Not modeled</td>
<td>Not modeled</td>
</tr>
<tr>
<td>Hospitalization</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> source: Law, Morris, and Wald meta-analysis.<sup>18</sup> <sup>b</sup> source: Law, Morris, and Wald. <sup>18</sup>
Table 1. Continued

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate (range in upper and lower bound estimates if a variation assumed according to age and/or sex)</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average cost (used for infrequent hospitalized drug-related adverse events)</td>
<td>$12,000 Not modeled Not modeled</td>
<td>National Inpatient Sample survey</td>
</tr>
<tr>
<td>High cost (used for rare hospitalized drug-related adverse events)</td>
<td>$21,000</td>
<td></td>
</tr>
<tr>
<td>Laboratory test (electrolytes monitoring on treatment)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of tests</td>
<td>1 1 2</td>
<td>U.S. Joint National Committee 7 recommendation Centers for Medicare and Medicaid laboratory fee schedule</td>
</tr>
<tr>
<td>Cost per test</td>
<td>$15 Not modeled Not modeled</td>
<td></td>
</tr>
<tr>
<td>Antihypertensive drug costs (total daily doses)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5 standard dose</td>
<td>$124 Not modeled $296</td>
<td>Average wholesale prices reported by manufacturers (“Red Book”; 2010), see Methods text for estimation method</td>
</tr>
<tr>
<td>1.0 standard dose</td>
<td>$166 $363</td>
<td></td>
</tr>
<tr>
<td>1.5 standard doses</td>
<td>$215 $409</td>
<td></td>
</tr>
<tr>
<td>2.0 standard doses</td>
<td>$238 $567</td>
<td></td>
</tr>
<tr>
<td>3.0 standard doses</td>
<td>$357 $850</td>
<td></td>
</tr>
<tr>
<td>3.5 standard doses</td>
<td>$430 $1,311</td>
<td></td>
</tr>
<tr>
<td>4.0 standard doses</td>
<td>$496 $1,374</td>
<td></td>
</tr>
<tr>
<td>Pharmacy dispensing fees</td>
<td>$27 $33</td>
<td></td>
</tr>
<tr>
<td>Acute and chronic CVD treatment costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction hospitalization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonfatal</td>
<td>$33,000</td>
<td>California Office of Statewide Health Planning and Development (OSHPD) hospital data, 2008</td>
</tr>
<tr>
<td>Fatal</td>
<td>$46,000</td>
<td></td>
</tr>
<tr>
<td>Coronary revascularization procedures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percutaneous coronary intervention</td>
<td>$21,000–$23,000</td>
<td></td>
</tr>
<tr>
<td>Coronary artery bypass graft surgery</td>
<td>$57,000–$59,000</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatal</td>
<td>$21,000–$26,000</td>
<td></td>
</tr>
<tr>
<td>Nonfatal</td>
<td>$15,000–$21,000</td>
<td></td>
</tr>
<tr>
<td>Chronic CHD costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>First year</td>
<td>$11,000</td>
<td>US Medical Expenditure Panel Surveys (MEPS), 1998–2008</td>
</tr>
<tr>
<td>Subsequent years</td>
<td>$2,000</td>
<td></td>
</tr>
<tr>
<td>Chronic post-stroke costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>First year</td>
<td>$16,000</td>
<td></td>
</tr>
<tr>
<td>Subsequent years</td>
<td>$5,000</td>
<td></td>
</tr>
<tr>
<td>Inflation from 2010 to 2014 costs</td>
<td>9% 11%</td>
<td>Main = change in general US consumer price index; upper = change in medical component</td>
</tr>
</tbody>
</table>

Serious adverse effects of medications (incidence per 100,000 person-years)

Common, outpatient management
<table>
<thead>
<tr>
<th>Variable</th>
<th>Main</th>
<th>Lower</th>
<th>Upper</th>
<th>Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 standard doses</td>
<td>10,039.20</td>
<td>6,950.21</td>
<td>12,742.06</td>
<td>Based on Law 2003¹⁷</td>
</tr>
<tr>
<td>2 standard doses</td>
<td>7,572.41</td>
<td>5,242.43</td>
<td>9,611.13</td>
<td></td>
</tr>
<tr>
<td>1 standard dose</td>
<td>5,200.00</td>
<td>3,600.06</td>
<td>6,600.00</td>
<td></td>
</tr>
<tr>
<td>0.5 standard dose</td>
<td>2,600.00</td>
<td>1,800.00</td>
<td>3,300.00</td>
<td></td>
</tr>
<tr>
<td>Infrequent, hospitalized</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 standard doses</td>
<td>193.06</td>
<td>19.31</td>
<td>965.31</td>
<td>Trials, medication labels, post-marketing reports</td>
</tr>
<tr>
<td>2 standard doses</td>
<td>145.62</td>
<td>14.56</td>
<td>728.12</td>
<td></td>
</tr>
<tr>
<td>1 standard dose</td>
<td>100.00</td>
<td>10.00</td>
<td>500.00</td>
<td></td>
</tr>
<tr>
<td>0.5 standard dose</td>
<td>50.00</td>
<td>5.00</td>
<td>250.00</td>
<td></td>
</tr>
<tr>
<td>Rare, hospitalized/severe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 standard doses</td>
<td>1.93</td>
<td>0.0193</td>
<td>19.31</td>
<td></td>
</tr>
<tr>
<td>2 standard doses</td>
<td>1.46</td>
<td>0.0146</td>
<td>14.56</td>
<td></td>
</tr>
<tr>
<td>1 standard dose</td>
<td>1.00</td>
<td>0.0100</td>
<td>10.00</td>
<td></td>
</tr>
<tr>
<td>0.5 standard dose</td>
<td>0.50</td>
<td>0.0050</td>
<td>5.00</td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 standard doses</td>
<td>0.0193</td>
<td>0.0002</td>
<td>0.1931</td>
<td></td>
</tr>
<tr>
<td>2 standard doses</td>
<td>0.0146</td>
<td>0.0001</td>
<td>0.1456</td>
<td></td>
</tr>
<tr>
<td>1 standard dose</td>
<td>0.0100</td>
<td>0.0001</td>
<td>0.1000</td>
<td></td>
</tr>
<tr>
<td>0.5 standard dose</td>
<td>0.0050</td>
<td>0.0001</td>
<td>0.0500</td>
<td></td>
</tr>
</tbody>
</table>

Utility (QALY weight penalty, duration)

<table>
<thead>
<tr>
<th>Drug side effects managed as outpatient (1 day)</th>
<th>0.23</th>
<th>Montgomery²³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug side effect requiring hospitalization (1 day)</td>
<td>0.50</td>
<td>Clinical judgment</td>
</tr>
<tr>
<td>Acute stroke (1 month)</td>
<td>0.86</td>
<td>Global Burden of Disease 2010 Study²⁴</td>
</tr>
<tr>
<td>Chronic stroke survivors (12 months)</td>
<td>0.85–0.88</td>
<td></td>
</tr>
<tr>
<td>Acute myocardial infarction (1 month)</td>
<td>0.91</td>
<td></td>
</tr>
<tr>
<td>Acute unstable angina (1 month)</td>
<td>0.95</td>
<td></td>
</tr>
<tr>
<td>Chronic CHD (12 months)</td>
<td>0.91–0.98</td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>1.00</td>
<td>Past cost-effectiveness analyses²⁵,²⁶</td>
</tr>
<tr>
<td>Disutility due to taking daily medications</td>
<td>0.00</td>
<td>0.01–0.02</td>
</tr>
<tr>
<td>Adherence to medications (percent of patients continuing prescribed treatment)</td>
<td>75%</td>
<td>Not modeled</td>
</tr>
<tr>
<td>Annual discount rate</td>
<td>3%</td>
<td>Not modeled</td>
</tr>
</tbody>
</table>

Abbreviations: BP = blood pressure; CHD = coronary heart disease; CVD = cardiovascular disease; QALY = quality-adjusted life year.

¹Relative risk reductions vary by age and sex category, see Methods and Supplementary Appendix for details.

²Change in BP dependent on age- and sex-specific distribution of baseline BPs within stage 1 or stage 2 category and number of standard dose antihypertensive medications.

³Standard dose medications used to estimate costs: captopril 25mg twice daily, nifedipine 30mg daily, amlodipine 5mg daily, hydrochlorothiazide 25mg daily, and atenolol 50mg daily. Combination medications equivalent to two-half standard doses were amlodipine/benazepril 2.5/10mg daily and captopril/hydrochlorothiazide 25/25mg daily. Combination medications equivalent to 1.5 standard doses were captopril/hydrochlorothiazide 25/25mg once daily, benazepril/amlodipine 10/2.5mg daily, or hydrochlorothiazide/propranolol 25/80mg daily. Combination medications equivalent to 2 standard doses were atenolol/chlorthalidone 50/25mg daily and captopril/hydrochlorothiazide 50/25mg daily. Of the medications listed, only captopril (angiotensin converting enzyme inhibitor) taken divided doses (25mg twice daily).

⁴Variation dependent on 90 or 100 pill packaging.
Table 2. Annual population treated and cost-effectiveness of implementing JNC 8 hypertension treatment guidelines in previously untreated non-Hispanic black (NHB) and non-Hispanic white (NHW) adults with hypertension aged 35–74 years. Average annual results from a years 2014–2024 simulation, the CVD policy model.

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Number of people newly treated</th>
<th>CVD events averted compared with status quo</th>
<th>CVD costs compared with status quo ($US, thousands)</th>
<th>ICER compared with status quo ($US per QALY gained)</th>
<th>ICER compared with prior strategy ($US per QALY gained)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NHB patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NHB women ages 35–74 years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treat CVD population</td>
<td>35,000</td>
<td>-1,000 (1,000; 1,000)</td>
<td>-48,000 (-70,000; -31,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat stage 2 along with CVD</td>
<td>484,000</td>
<td>-2,000 (2,000; 3,000)</td>
<td>-103,000 (-142,000; -73,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat stage 1 with diabetes or CKD, along with CVD and stage 2</td>
<td>703,000</td>
<td>-3,000 (2,000; 3,000)</td>
<td>-112,000 (-157,000; -76,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat all hypertension</td>
<td>855,000</td>
<td>-3,000 (3,000; 4,000)</td>
<td>-115,000 (-164,000; -76,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td><strong>NHB men ages 35–74 years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treat CVD population</td>
<td>96,000</td>
<td>-1,000 (1,000; 2,000)</td>
<td>-100,000 (-148,000; -67,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat stage 2 along with CVD</td>
<td>592,000</td>
<td>-4,000 (3,000; 5,000)</td>
<td>-258,000 (-336,000; -193,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat stage 1 with diabetes or CKD, along with CVD and stage 2</td>
<td>698,000</td>
<td>-4,000 (4,000; 6,000)</td>
<td>-294,000 (-386,000; -219,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat all hypertension</td>
<td>940,000</td>
<td>-5,000 (4,000; 7,000)</td>
<td>-337,000 (-446,000; -244,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td><strong>NHW patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NHW women ages 35–74 years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treat CVD population</td>
<td>86,000</td>
<td>-4,000 (3,000; 5,000)</td>
<td>-163,000 (-240,000; -105,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat stage 2 along with CVD</td>
<td>785,000</td>
<td>-10,000 (8,000; 12,000)</td>
<td>-286,000 (-431,000; -160,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat stage 1 with diabetes or CKD, along with CVD and stage 2</td>
<td>1,527,000</td>
<td>-11,000 (9,000; 13,000)</td>
<td>-273,000 (-440,000; -130,000)</td>
<td>Cost saving*</td>
<td>6,000 (-4,000; 18,000)</td>
</tr>
<tr>
<td>Treat all hypertension</td>
<td>2,559,000</td>
<td>-13,000 (10,000; 15,000)</td>
<td>-203,000 (-399,000; -43,000)</td>
<td>Cost saving*</td>
<td>19,000 (9,000; 31,000)</td>
</tr>
<tr>
<td><strong>NHW men ages 35–74 years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treat CVD population</td>
<td>482,000</td>
<td>-6,000 (5,000; 8,000)</td>
<td>-455,000 (-702,000; -292,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat stage 2 along with CVD</td>
<td>1,368,000</td>
<td>-16,000 (12,000; 20,000)</td>
<td>-884,000 (-1,269,000; -597,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat stage 1 with diabetes or CKD, along with CVD and stage 2</td>
<td>1,961,000</td>
<td>-19,000 (14,000; 24,000)</td>
<td>-964,000 (-1,399,000; -632,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
<tr>
<td>Treat all hypertension</td>
<td>3,436,000</td>
<td>-22,000 (18,000; 28,000)</td>
<td>-971,000 (-1,473,000; -581,000)</td>
<td>Cost saving*</td>
<td>Cost saving*</td>
</tr>
</tbody>
</table>

Abbreviations: CKD = chronic kidney disease; CVD = cardiovascular disease; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life year.
*Upper and lower uncertainty interval bounds of ICERs were cost saving.
Vasudeva et al.

American Journal of Hypertension

95% UI $3,000–$43,000) and in those without diabetes or CKD ($46,000/QALY; 95% UI $17,000–$76,000).

Treating hypertension was cost saving in all non-Hispanic white men with stage 2 hypertension and those aged 45–74 years with stage 1 hypertension. Treatment was cost-effective in non-Hispanic white males aged 35–44 years with stage 1 hypertension and diabetes or CKD with an ICER of about $5,000/QALY gained (95% UI from cost saving to $30,000), but of only intermediate value in those with stage 1 hypertension but without diabetes or CKD (ICER of about $57,000/QALY; 95% UI $15,000–$100,000). In non-Hispanic white females, hypertension treatment was only cost saving in those 45–74 years old and with stage 2 hypertension. Treating non-Hispanic white women aged 35–44 years with stage 2 hypertension or those aged 45–74 years with stage 1 hypertension was cost-effective (Figure 1). Treating hypertension in white women aged 35–44 years with stage 1 hypertension was of intermediate or low value (ICERS ≥ $50,000/QALY; 95% UI $46,000–$121,000 with diabetes or CKD, $111,000–$235,000 without diabetes or CKD).

For non-Hispanic whites with stage 1 hypertension but without diabetes or CKD, lifestyle interventions alone would result in about 1,000–3,000 CVD events avoided per year, less than the approximately 1,000 events that would be prevented by pharmacologic treatment alone.

### DISCUSSION

Implementation of 2014 hypertension treatment guidelines would reduce CVD morbidity and mortality while saving costs overall in both non-Hispanic whites and blacks with untreated hypertension. Compared with non-Hispanic whites, cost savings and cost-effectiveness extended to younger ages in non-Hispanic black patients with stage 1 hypertension. In the short term, implementing guideline goals would be cost-effective in 35- to 44-year-old non-Hispanic black females with stage 1 hypertension, but appeared to be of intermediate or low value in non-Hispanic white females of the same age and hypertension stage.

Over 41% of non-Hispanic blacks aged ≥18 years have hypertension, more than 10 percentage points higher than other US race/ethnic groups. Awareness and treatment have improved in all US adults in the past 2 decades, but even now only about a half of non-Hispanic whites have controlled hypertension (50.3%), and the proportion controlled is almost 9 percentage points lower in non-Hispanic blacks (41.4%).

Uncontrolled hypertension is a leading cause of death and

---

**Table 1.** Incremental cost-effectiveness of implementing JNC 8 hypertension treatment guidelines in previously untreated non-Hispanic black (NHB) and non-Hispanic white (NHW) adults with hypertension aged 35–74 years, by age, sex, hypertension stage, and status of diabetes or chronic kidney disease (CKD). Within age and sex row, each group is compared with the higher risk group to its left; stage 2 hypertension is compared with patients living with cardiovascular disease (CVD) and hypertension. Average annual results from a years 2014–2024 simulation, the CVD policy model. Abbreviation: ICER = incremental cost-effectiveness ratio.

**Figure 1.** Incremental cost-effectiveness of implementing JNC 8 hypertension treatment guidelines in previously untreated non-Hispanic black (NHB) and non-Hispanic white (NHW) adults with hypertension aged 35–74 years, by age, sex, hypertension stage, and status of diabetes or chronic kidney disease (CKD). Within age and sex row, each group is compared with the higher risk group to its left; stage 2 hypertension is compared with patients living with cardiovascular disease (CVD) and hypertension. Average annual results from a years 2014–2024 simulation, the CVD policy model. Abbreviation: ICER = incremental cost-effectiveness ratio.
disability in the non-Hispanic black population, and non-Hispanic black men have the highest rates of hypertension-related death (hypertensive heart disease, other heart diseases, and stroke) of any race/ethnic group. Hypertension treatment and control in non-Hispanic black adults is therefore an urgent national public health priority. Our results suggest that implementing hypertension treatment guidelines in younger non-Hispanic black adults is a high-value strategy for health system payers, yielding cost savings in older and higher risk patients, and cost-effectiveness in younger patients.

Clinical practice-based studies have demonstrated that intensive focus on hypertension treatment can lead to remarkable improvements in BP control. Investment in a team-based approach—supplementing usual care with intensive interactions between patient and a nonphysician health care provider—may achieve substantial gains. Non-Hispanic black men aged 21–54 years old in inner-city Baltimore who received educational-behavioral-pharmacologic intervention from a team including a nurse practitioner and community health worker had a >10% higher proportion of controlled hypertension after a 36-month intervention, compared with those receiving usual care. A systematic clinic-based quality improvement intervention in the 15 Veteran’s Administration medical centers achieved a >30% point improvement in hypertension control over 10 years, with similar improvements in non-Hispanic black and white patients. A multicomponent intervention combining patient education, home BP monitoring, and lifestyle counseling in low-income non-Hispanic black patients (72% female) did not improve hypertension control compared with usual care—in part perhaps because the complexity of the intervention led to <50% adherence to component interventions. The results of the SPRINT trial add to decades of evidence demonstrating that BP-lowering therapies save lives. Further research is needed on the most effective ways to deliver this highly effective and cost-effective therapy to all patients seen in clinical practice, including non-Hispanic black patients. Lifestyle interventions alone in stage 1 patients without diabetes or CKD would prevent a more modest number of CVD events compared with pharmacologic therapy alone; however, lifestyle changes are likely to augment prevention benefits when combined with pharmacologic treatment or serve as an alternative for patients who decline to take medications.

Due in part to documented barriers to accessing and accepting treatment, a significant proportion of non-Hispanic black patients do not regularly seek hypertension and other preventive care in medical clinics. Recent initiatives have tested the strategy of diagnosing and initiating treatment in non-Hispanic black adults outside of the clinic and in other community settings, including barbershops, community centers, and faith-based organizations. In the intervention arm of a trial in Dallas, barbers in 17 black-owned barbershops were trained to offer BP checks, deliver health education, and refer hypertensive patients to medical care. After 10 months, hypertension control was 8.8 percentage points higher in the intervention, compared with the usual care arm. The Georgia Stroke and Heart Attack Prevention Program (SHAPP) is a statewide initiative focused on hypertension screening and control in 16 predominantly rural public health districts that are about 56% non-Hispanic black. Through provider training, affordable medications, adherence support, and community partnerships, SHAPP achieved approximately 60% hypertension control and was projected to save costs compared with no treatment. Our analysis provides further evidence supporting the value of investing in both clinic- and community-based interventions to improve hypertension control in non-Hispanic blacks and other high-risk groups with high hypertension prevalence.

The methods and reporting of this study conform to Consolidated Health Economic Evaluation Reporting Standards (CHEERS; see checklist in the Supplementary Text), and Quality of Health Economic Studies Instrument standards recommended for cost-effectiveness analyses of US CVD risk factor guidelines. Effectiveness assumptions were grounded in a large meta-analysis of randomized anti-hypertensive medication treatment trials and inputs for non-Hispanic whites and blacks were estimated from national data. However, like all computer-simulation analyses, this analysis was limited by reliance on multiple assumptions and inputs derived from multiple data sources and study types. Because of our conservative approach, we did not fully capture disability and health care costs attributed to hypertensive heart disease or end-stage renal disease—both of which are more common in non-Hispanic blacks—so that we may have underestimated cost savings and QALY gains with hypertension treatment compared with no treatment and in between-group comparisons. Additionally, while the 2014 national guidelines recommended different first-line agents for hypertension control in non-Hispanic blacks (diuretics or calcium channel blockers) and whites (the same agents or renin-angiotensin system blockers), the BP response to different agents is similar in most patients, and we chose not to model differential use of antihypertensive medication classes in order not to bias cost-of-treatment inputs. Our projections of future CVD incorporated demographic trends but did not account for any secular or clinical practice changes in the next decade. Our analysis is further limited by its exclusion of other race/ethnic groups, including Hispanic Americans and Asian Americans due to the lack of high-quality data on stroke and coronary heart disease incidence in these groups. Further research is needed to elucidate hypertension treatment cost-effectiveness in these groups as higher quality data becomes available.

Hypertension treatment cost savings and cost-effectiveness extend to younger ages among non-Hispanic black, compared with non-Hispanic white patients. Given their higher hypertension prevalence and heavier burden of hypertension-related disease compared with any other US race/ethnic group, investment in effective clinic- and community-based hypertension control programs in non-Hispanic black Americans is a particularly high-value investment in population health.

SUPPLEMENTARY MATERIAL

Supplementary materials are available at American Journal of Hypertension (http://ajh.oxfordjournals.org).
ACKNOWLEDGMENTS

This work was supported by funds from NHLBI (R01 HL107475-01), NINDS (5-U54NS081760-03), the American Heart Association Founder’s Affiliate (10CRP4140089), and HRSA (T32HP10260). This manuscript was prepared using Framingham Cohort and Framingham Offspring Research Materials obtained from the US National Heart, Lung and Blood Institute (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the Framingham Cohort, Framingham Offspring, or the NHLBI. Kirsten Bibbins-Domingo is a member of the US Preventive Services Task Force (USPSTF) and current co-Vice Chair. This work does not necessarily represent the views and policies of the USPSTF. Eshan Vasudeva and Andrew Moran had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Moran; Acquisition of data: Vasudeva, Coxson, and Moran; Analysis and interpretation of data: Vasudeva and Moran; Drafting of the manuscript: Vasudeva, Moran, and Moise; Critical revision of manuscript for important intellectual content: Moran, Coxson, Bibbins-Domingo, Goldman, and Moise; Statistical analysis: Vasudeva, Huang, and Moran; Obtained funding: Moran; Study supervision: Moran.

DISCLOSURE

The authors declared no conflict of interest.

REFERENCES


